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Abstract. Novel nanoparticle-aggregate formulations containing recombinant hepatitis B surface antigen
(rHBsAg) were administered to the lungs of guinea pigs and antibodies generated to this antigen
evaluated. Preparations of dry powders of: (a) rHBsAg encapsulated within poly(lactic-co-glycolic acid)
(PLGA)/polyethylene glycol (PEG) nanoparticles (antigen nanoparticles, AgNSD), (b) rHBsAg in a
physical mixture with blank PLGA/PEG nanoparticles (antigen nanoparticle admixture (AgNASD), and
(c) rHBsAg encapsulated in PLGA/PEG nanoparticles plus free rHBsAg (antigen nanoparticles and free
antigen), were generated by spray drying with leucine. Control groups consisted of alum with adsorbed
rHBsAg (AlumAg); reconstituted suspensions of spray-dried rHBsAg-loaded PLGA/PEG nanoparticles
with leucine; and rHBsAg-loaded PLGA/PEG nanoparticles (AgN). Control preparations were
administered by intramuscular injection; AgN was also spray instilled into the lungs. The IgG titers
were measured in the serum for 24 weeks after the initial immunization; IgA titers were measured in the
bronchio-alveolar lavage fluid. While the highest titer of serum IgG antibody was observed in guinea pigs
immunized with AlumAg administered by the IM route, animals immunized with powder formulations
via the pulmonary route exhibited high IgA titers. In addition, guinea pigs immunized with AgNASD via
the pulmonary route exhibited IgG titers above 1,000 mIU/ml in the serum (IgG titers above 10 mIU/ml
is considered protective). Thus, the disadvantages observed with the existing hepatitis B vaccine
administered by the parenteral route may be overcome by administering them as novel dry powders to
the lungs. In addition, these powders have the advantage of eliciting a high mucosal immune response in
the lungs without traditional adjuvants.
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INTRODUCTION
Hepatitis B virus (HBV) has infected 2 billion people
worldwide, and 350 million live with chronic hepatitis B
infection (1). Although an effective vaccine against hepatitis B
has been available since 1982, an estimated 1 million deaths
result from hepatitis B virus-related hepatocellular carcinoma
each year suggesting that current strategies for vaccines are
inadequate (2). Hepatitis B is a highly contagious virus trans-
mitted by percutaneous (puncture through the skin) or per-
mucosal (direct contact with mucous membrane) exposure to
blood or other body fluids. It is 50-100 times more infectious
thanHIVand causes chronic liver diseases leading to death from
cirrhosis of the liver and liver cancer (1). Southeast Asia and
Sub-Saharan Africa are areas of endemic HBV, where 10–20%
of the population is sero-positive for hepatitis B surface antigen
(3). Modes of transmission of HBV include mother-to-infant,
child-to-child, unsafe injection practices, blood transfusions, and
sexual contact. Thus, there is a perceived need for a better
vaccine that will enable greater coverage around the world and
decrease the incidence of HBV-related chronic liver disease and
hepato-cellular carcinoma.
Conventional hepatitis B vaccine is administered as an
intramuscular (IM) injection along with other vaccines as part of
the mass immunization program. The IM route poses at least
two problems to safety and efficacy of hepatitis B immunization.
First, and further discussed below, is the problem of dirty
needles, a serious concern in many parts of the world where
immunizations take place. Second, the probability of a local
reaction at the site of injection is pronounced when multiple
vaccines are administered simultaneously. For this latter reason
alone, a non-injectable route of vaccine administration for the
mass immunization program would likely improve safety and
possibly efficacy of hepatitis B vaccination.
Hepatitis B vaccine containing alum is reported to
produce nodules and erythema at the site of injection (4).
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Extrinsic factors such as freezing of the vaccine have been
associated with decreased immune response; freezing dissoci-
ates the antigen from the alum, and thus, interferes with the
vaccine’s immunogenicity. None of the currently licensed
adjuvants in humans are suitable for mucosal immunization (5).
Development of mucosal immunity is critical as the
existing vaccine administered by the parenteral route usually
fails to induce this desirable feature that might reduce disease
dissemination (6). Mucosal immunity plays an important role
by preventing the attachment of virus to the mucosa (7).
Mucosal vaccination does not require trained medical person-
nel or needles and syringes, and could be an attractive route
of administration for mass vaccination in developing countries
(8). Novel hepatitis B vaccines administered by the intranasal
route to different species of animals has been shown to elicit a
strong mucosal immune response (6,7,9–11). However,
mucosal immunization caused systemic tolerance (12); the
down-regulation of IgG due to systemic tolerance in the
circulation may cause chronic infection. Consequently, alter-
native approaches should be explored.
Needle-free Immunization
As part of the mass immunization program in developing
countries, billions of injections are delivered. The trans-
mission of blood borne pathogens is thought to be a major
global public health problem. Each year, an overwhelming
number of infections with HBV (8-16 million) are thought to
originate from the reuse of needles and syringes by health-
care providers (13); this translates to 32% of HBV infections
in developing countries (14). In fact, the present hepatitis B
vaccine poses a greater risk for needle-based transmission of
infectious diseases than through exposure to infectious blood,
body fluids, or by personal contact (15,16). The disposal of
waste (biologically contaminated sharps and syringes) after a
mass immunization program is also a deterrent to vaccination,
especially in developing countries. This has driven the Grand
Challenges in Global Health to stress the development of
needle-free vaccine delivery for different diseases (17).
Antigen-presenting cells such as alveolar macrophages
and dendritic cells that are ideally located in the lungs for
antigen sampling and subsequent presentation to T-cells,
making pulmonary delivery of vaccines desirable (18–20).
Increased vaccine efficacy when delivered by the pulmonary
route may be explained by prolonged residence of the antigen
in the alveoli and their subsequent migration to lymphoid
tissues compared to vaccines administered by other routes
where the antigen is transiently present before it is cleared
from the body.
The challenges of pulmonary administration include
delivery of adjuvant material and the nature of formulation.
Given the possibility of an immunotoxicological response
associated with the delivery of traditional adjuvants (such as
alum with hepatitis B vaccine) to the lungs, pulmonary
formulations of vaccines must achieve adjuvancy by a more
specific or localized mechanism, amplifying antigenicity while
avoiding serious side effects. Liquid formulations, while easy
to prepare, are frequently limited by their stability, shelf life,
and requirement for expensive transport and distribution
controls. Dry powder forms of vaccine for pulmonary delivery
have been used in humans and animal models of disease for
prevention of, for example, tuberculosis, influenza, diphthe-
ria, and measles (21–23). The preparation of dry forms of
hepatitis B vaccines requires the formulation of the vaccine in
a dry state, and administration with material that can serve as
an effective adjuvant in the absence of alum. One potential
material is biodegradable polymer, which can be used to
encapsulate the vaccine. The resulting biodegradable nano-
particles must then be formed into aggregates with a mass
median aerodynamic diameter (MMAD) between 1 and 5 μm
for effective delivery to the lungs, a challenge that can
potentially be met using “porous nanoparticle aggregate
particle” (PNAP) technology as previously developed (24,25).
Pulmonary delivery of hepatitis B vaccine as a dry
powder for mass vaccination campaign has the potential to
address the following critical issues: the need to increase
efficacy that confers better local mucosal as well as systemic
immunity; the need to demonstrate safety during adminis-
tration by reducing the risk of contamination by sharps and
needles; the need to eliminate powder reconstitution, thus,
increasing stability during transport and administration; and
the need to improve cost effectiveness.
However, there are no published clinical or experimental
data for pulmonary vaccination series with rHBsAg powder.
A recombinant form of HBsAg is preferred due to disadvan-
tages associated with the use of native antigen including: the
time consuming manufacturing process; the high costs of
production for mass immunization, which are untenable for
poor countries; the poor supply of large amounts of human
plasma; and a lengthy adverse reaction test in chimpanzees
for the plasma derived antigen.
Therefore, the following study addresses the immunoge-
nicity of pulmonary vaccination with rHBsAg, delivered as dry
PNAP forms and as liquid suspensions and by different routes of
administration, as determined by the serum IgG and lung IgA
responses in guinea pigs. Novel dry powder formulations
containing rHBsAg (Fig. 1 and Table I) were prepared and
characterized with the potential for deep lung delivery. They
were administered to guinea pigs at different time periods and
blood was withdrawn at regular intervals to estimate the serum
IgG antibody titers. Lung IgA antibody titers were evaluated at
the time of sacrifice of the guinea pigs.
MATERIALS AND METHODS
Materials
Goat anti-guinea pig IgG peroxidase conjugate was
purchased from Sigma Aldrich (Sigma, Saint Louis, MO,
USA) and sheep anti-guinea pig IgA peroxidase conjugate
procured from ICL Inc. for the in-vivo enzyme-linked
immunosorbent assay (ELISA). Anti-HBs enzyme immuno-
assay (EIA) and calibrator kit (Monolisa™, BIO-RAD,
Redmond, WA, USA) was used for the quantification of
IgG antibody (milli International Units per milliliter) to
rHBsAg in guinea pig serum. All other chemicals used were
of analytical grade.
Methods
Poly(lactic-co-glycolic acid) (PLGA)/polyethylene glycol
(PEG) nanoparticles composed of a PLGA core and a PEG
331Immunization by Pulmonary Route with Dry Powders
shell, with or without rHBsAg, were prepared by the double
emulsion method. The particle size, polydispersity index, and
zeta potential of PLGA/PEG nanoparticles as measured by
photon correlation spectroscopy and laser Doppler anemom-
etry (Zetasizer, Malvern instruments, UK) were 160±22 nm,
0.16 and −20 mV, respectively. The entrapment efficiency of
the antigen within the PLGA/PEG nanoparticles taking into
account a theoretical loading of 2% was 52.2±5.1% as
determined by ELISA.
Dry powder formulations with excellent aerosolization
properties for pulmonary delivery were obtained by spray
drying. Aqueous suspensions of rHBsAg encapsulated
PLGA/PEG nanoparticles or PLGA/PEG nanoparticles
alone were spray dried (Niro atomizer, Columbia, MD,
USA) with a solution of L-leucine. The ratio of nanoparticles
to leucine was kept at 10/90. The inlet and outlet temper-
atures of the spray drier were maintained at 80°C and 33°C,
respectively. The feed rate of the solution was 30 ml/min, and
the air flow rate 98 kg/h.
The different forms of rHBsAg spray dried with leucine
were: (1) free rHBsAg with PLGA/PEG nanoparticles alone
(AgNASD), (2) rHBsAg encapsulated in PLGA/PEG nano-
particles (AgNSD), (3) rHBsAg encapsulated PLGA/PEG
nanoparticles and free rHBsAg in a physical mixture
(AgNFSD). The theoretical loading of rHBsAg in the first
two formulations was 10 µg/mg dry powder-1, whereas it was
20 µg for the third powder (Table I and Fig. 1). All the dry
powder formulations showed good properties for deep lung
delivery based on the geometric standard deviation (GSD),
MMAD, density, and water content.
The geometric diameter of the spray-dried powders as
measured by laser light diffraction (Sympatec, Germany) with
powder dispersion (Rodos, Sympatec, Germany) was around
7.0 µm. The MMAD and fine particle fractions (FPF)
determined by the Andersen eight stage non-viable cascade
impactor (ACI) was around 4.80 µm and 50%, respectively,
based on a particle size cut-off of <5.8 µm. Tap density was
obtained using a Varian Tap Density machine by measuring
the volume of a known amount of powder after tapping it for
500 times and was 0.048 g/ml. Water content of the spray-
dried powders as measured by Karl Fisher method was less
than 1%.
SEM was used to elucidate the structures of the PLGA/
PEG nanoparticles after spray drying with leucine. Hollow
and low density particles with a rough inner surface probably
due to the presence of intact nanoparticles were obtained
when PLGA/PEG nanoparticles were spray dried at a low
outlet temperature of 33°C.
Vaccination and Immunization Schedule
All animal procedures were approved by the University of
North Carolina, Chapel Hill Institutional Animal Care and Use
Committee. Male guinea pigs weighing 350-400 g (Hilltop
Table I. The Composition of the Dry Powder Vaccines, their Dose and Route of Administration to Guinea Pigs
Formulation Nomenclature Composition Antigen loading (µg) Route of administration
AgNSD Antigen Nanoparticles-Spray
Dried





rHBsAg in a physical mixture with
blank PLGA/PEG nanoparticles
10 Insufflation
AgNFSD Antigen Nanoparticles and Free
antigen-Spray Dried
rHBsAg encapsulated in PLGA/PEG
nanoparticles plus free rHBsAg
20 Insufflation
AgN Antigen Nanoparticles rHBsAg-loaded PLGA/PEG nanoparticles 10 Intramuscular
ReconAgNSD Reconstituted Antigen
Nanoparticles-Spray Dried
Reconstituted spray dried rHBsAg
loaded PLGA/PEG nanoparticles
10 Intramuscular
AlumAg Alum with Antigen Alum with adsorbed rHBsAg 10 Intramuscular
AgN Antigen Nanoparticles rHBsAg-loaded PLGA/PEG nanoparticles 10 Spray instillation
Fig. 1. The study design consisting of the various vaccine formulations, their route of administration to guinea
pigs and immunization and bleeding schedule (Insuff insufflation, IM intramuscular, Inst spray instillation)
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LaboratoryAnimals, Inc., Scottsdale, PA,USA) were housed in
a 12-h light/12-h dark cycle and constant temperature of 22°C.A
standard diet and water were supplied ad libitum. Animals were
randomly assigned to seven different groups (n=6 each) and
immunized with novel rHBsAg formulations and administered
as dry powders/suspensions as shown in Fig. 1 and Table I.
Figure 1 also summarizes the time intervals between the four
immunizations. Table I shows the various formulations admin-
istered to guinea pigs, their composition, antigen loading, and
route of administration. Guinea pigs were anesthetized with
ketamine, xylazine and acepromazine (3:1:0.5) administered by
the subcutaneous route in the nape of the neck. Untreated
animals were used as negative controls. Dry powder formula-
tions containing rHBsAg were administered to anesthetized
animals by insufflation. Approximately 10 mg of the powder,
corresponding to 10/20 µg of rHBsAg, were administered with a
DP-4 insufflator (Penn Century, Inc., Philadelphia, PA, USA).
Briefly, anesthetized guinea pigs were placed on their abdomen
on a flat surface and the tracheal opening located by inserting a
fiber optic laryngoscope (Fiber-Lite system 181-1 Dolan-Jenner
Industries, Inc., Woburn, MA, USA) into the mouth of the
animal. The DP-4 insufflator was loaded with the required
amount of powder and inserted into the tracheal opening until
the insufflator reached a few millimeters from the carina of the
lung for proper aerosolization of the powder. The dry powder
was delivered into the lungs of the guinea pigs by pumping air
with a 5-ml disposable plastic syringe attached to the other end
of the insufflator. The delivered dose was determined by
subtracting the weight of the insufflator after powder admin-
istration from that of the insufflator before administration. The
loss of powder adhering inside the insufflator was not greater
than 1 mg; consequently, the dose +1 mg was loaded to
compensate this loss.
For spray liquid instillation, the Microsprayer® (Penn
Century, Inc., Philadelphia, PA, USA) connected to a
prefilled Hamilton gas-tight syringe (1,000 cc) was inserted
into the oro-pharyngeal tube. Subsequently, 100 µl of the
vaccine suspension containing 10 µg of the rHBsAg in saline
was instilled. Intramuscular immunizations were performed in
the calf muscle of anesthetized guinea pigs with the antigens
suspended in sterile phosphate-buffered saline; a volume of
100 µl was injected. In all the cases, the immune responses
were followed for 6 months after the prime immunization.
Measurement of In-vivo Antibody Response
ELISA
Blood was collected at intervals, as shown in Fig. 1, from
anesthetized animals by the saphenous vein and serum
recovered by centrifugation; final bleeding was carried out
at 24 week after the first immunization. After the final bleed,
bronchio-alveolar lavage was performed on the guinea pigs.
Sera and lavage fluids were stored in aliquots at −80°C prior
to analysis and frozen samples thawed only once before
analysis.
Anti-HBs IgG titer was measured in pooled and
individual serum samples by indirect ELISA. Briefly, 96 well
flat-bottom immuno plates (MaxiSorp, Nalge NUNC Interna-
tional, Rochester, NY, USA) were coated with rHBsAg in
50 µl/well of coating buffer (50 mM carbonate buffer, pH9.6)
at a concentration of 2.5 µg/ml at 4°C overnight. The plates
were washed four times with wash buffer (phosphate-
buffered saline (PBS), 0.05% Tween 20 (Sigma, St. Louis,
MO, USA)) and blocked to prevent non-specific binding at
37°C for 2 h with 150 µl/well blocking buffer (PBS, 0.05%
Tween 20, 1% bovine serum albumin). The blocking buffer
was aspirated and the plates washed four times with wash
buffer. Pooled and individual serum samples diluted in
blocking buffer were added to the plates at a starting dilution
of 1:200 and further diluted twofold across the plates. The
plates were incubated at 37°C for 1 h with 50 µl/well of each
serum dilution. After aspirating the serum dilutions and
washing four times, the plates were incubated for another
1 h at 37°C with 50 µl/well with anti-guinea pig IgG
peroxidase conjugate diluted 1/8,000 in blocking buffer. After
aspirating the conjugate and the final four washes, the
plates were developed with the substrate o-phenylenediamine
(OPD, Sigma, Saint Louis, MO, USA) for 30min at 37°C in the
dark. The substrate consisted of one tablet (10 mg) of OPD,
20 ml citrate buffer (50 mM, pH4.9), and 15 µl of 30% H2O2.
The reaction was stopped after 30 min by adding 50 µl/well of
3MHCL solution to the plates and optical density measured at
485 nm with 570 nm as the reference wavelength (Multi-
detection microplate reader, Synergy HT; Bio-Tek). Relative
antibody titers were determined by comparison to a curve
generated with sera from rHBsAg-alum immunized guinea pig
and expressed as the reciprocal of the endpoint dilution which
yielded an absorbance value at least three times background
levels. All samples were analyzed in duplicate.
In addition, to compare IgG titers with clinically
relevant values, anti-HBs IgG were also measured (in
triplicate) using the commercial Monolisa™ Anti-HBs EIA
Diagnostic Kit and quantification in milli International
Units per milliliter was performed following instructions
provided by the manufacturer.
IgA antibody titers were evaluated in the bronchio-
alveolar lavage fluid at the end of the study when the guinea
pigs were sacrificed. Guinea pigs were anesthetized as
described earlier and the trachea isolated by a midline
incision. Animals were tracheostomized, and a 14-gage
stainless steel catheter was secured with a suture. The animals
were exsanguinated, and the lungs gently perfused three
times with 3 ml of saline at room temperature. Recovery
volume was ≥80%. The lavage fluid was centrifuged and the
saline supernatant was assayed for IgA antibody titers by
ELISA. The protocol followed was same as for the evaluation
of IgG titers except that the anti-guinea pig IgG secondary
antibody was replaced with sheep anti-guinea pigs IgA
peroxidase conjugate at a dilution of 1/2,000 in blocking
buffer. Non-diluted BAL samples from individual guinea pigs
were added to the plates, and further diluted twofold across
the plates.
Statistical Analysis
One-way ANOVA was used to compare the data. Post-
hoc pair wise comparisons were conducted using Holm-Sidak
multiple comparison method when the differences in the
means were significant (Sigmaplot version 11, Systat Soft-
ware, Inc., California, USA). P values of less than 0.05 were
considered statistically significant.
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RESULTS
Humoral Antibody Response
Various dry powder vaccine formulations containing
rHBsAg were administered to guinea pigs by the pulmonary
route and the immune response elicited, based on serum IgG
and lungs IgA, assessed. Anti-HBs IgG and IgA titers were
measured using indirect ELISA (Figs. 2 and 3) and quantified
(in milli International Unit per milliliter) using the Mono-
lisa™ kit (Fig. 4). Significant increases in IgG antibody titers
were observed in all groups after the third boost immuniza-
tion except the insufflated AgNSD group. Only a slight
increase in titer levels was detected in this latter case after
three boosts. In contrast, the same dry powder formulation
administered by the IM route elicited high antibody titers
especially after the third boost. In the AgNASD administered
group by the pulmonary route, an increase in antibody titers
was observed after the third boost. Peak levels of titers were
achieved 15 days after the third boost and remained
unchanged till the end of the study (45 days after the last
boosting, Fig. 2a). Peak expressions of antibodies were
observed at 15 days following the third boost in groups of
guinea pigs receiving antigen encapsulated in nanoparticles
by injection and spray instillation, but antibody levels were
not sustained beyond 30 days. A higher antibody response
Fig. 2. Anti-hepatitis B surface antigen specific serum IgG titers in
guinea pigs after one prime and three boost immunizations with dry
powder formulations administered by pulmonary route (a) and with
suspension formulations by IM route (b). Responses are compared to
the surface antigen adsorbed alum control administered IM. Error
bars represent the mean±standard error. Arrows indicate the
immunization schedule which corresponds to 0, 4, 8 and 18 weeks.
Antibody titers are expressed as the reciprocal of the sample dilution
corresponding to at least three times the background level
Fig. 3. The last time point (week24) anti-hepatitis B surface antigen
specific serum IgG (a) and bronchio-alveolar lavage IgA (b) antibody
titers in guinea pigs after one prime and three boost immunizations
with different novel formulations administrated by the pulmonary
and intramuscular routes. Error bars represent the mean±standard
error. Antibody titers are expressed as the reciprocal of the sample
dilution corresponding to at least three times the background level. a
*P<0.001, results are significantly different than all other treatment
groups; b *P<0.002, significant differences compared to #
Fig. 4. The last time point (week24) IgG antibody titers in milli
International Unit per milliliter in the serum guinea pig after admin-
istration of dry powder formulations by the pulmonary and intramuscular
routes. Error bars represent the mean±standard error. *P<0.001, results
are significantly different than all other treatment groups
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was elicited in guinea pigs when AgN were administered by
the IM route rather than by spray instillation (Fig. 2b).
IgG antibody titers increased after AgNSD or AgNFSD
powders were administered by the pulmonary route. A
significant increase in antibody titers was observed 15 days
after the third boost, which was similar to the response
observed to AgNASD administered by insufflation. However,
antibody levels began to wane after 30 days (Fig. 2a).
Comparing Fig. 4 with Fig. 3a, it is apparent that the IgG
values inmilli InternationalUnit per milliliter were proportional
to the values obtained by indirect ELISA for the samples
collected at the last time point (week24). The AlumAg group
administered by the IM route elicited a significantly higher IgG
immune response compared to other formulations administered
by IM and pulmonary route (P<0.001).
Although IgG titers generated by administering antigen via
the pulmonary route to guinea pigs were below those of
AlumAg administered IM, the values were sufficient to provide
protection (IgG≥1,000 mIU/ml in all insufflated groups, Fig. 4).
Interestingly, the IgA antibody titers elicited in the lungs
of guinea pigs were higher in the group receiving the novel
dry powder formulations by the pulmonary route compared
to the group administered by the IM route (Fig. 3b). AgNFSD
elicited a significantly higher IgA response 24 weeks after the
first immunization compared to reconAgNSD and AlumAg
administered by the IM route (P<0.002). An immunological
advantage is clearly afforded by pulmonary administration
with respect to eliciting mucosal immunity.
DISCUSSION
Immunization by the pulmonary route in the prophylaxis
and therapy of infectious diseases is still in its early stages
(26). The purpose of this study was to investigate the
possibility of inducing anti-HBs IgG in the serum and IgA
titers in the lung of guinea pigs after administering novel dry
powder formulations by the pulmonary route.
Nanoparticles have been pursued in drug and vaccine
delivery because of their ability for enhanced absorption and
better migration through tissues and cells. Since nanoparticles
have the tendency to agglomerate due to their high surface-
to-volume ratio, they have been incorporated into porous
microparticles through spray drying to form structures that
may contain varying proportion of nanoparticles. Once
delivered to the deep lung, these appropriately sized for-
mulations will collapse to release the nanoparticles in the
alveolar region.
In the present study, dry powders intended for vaccine
delivery were based on the PNAP technology (24,25). To
better understand the effect of formulation type, PLGA/PEG
nanoparticles containing rHBsAg and spray dried with
leucine were used to obtain a dry powder aerosol formula-
tion. The selection of PLGA/PEG copolymer was based on
its extensive application in the biomedical and tissue engi-
neering fields. In the form of nanoparticles, it was feasible to
entrap a significant amount of rHBsAg thus preserving its
structural integrity.
After spray drying PLGA/PEG nanoparticles either
containing the antigen within the structure, free as a physical
mixture or both (encapsulated and free), the nanoparticles
were able to stabilize rHBsAg, thus preserving its antigenicity
as determined by ELISA. The geometric diameter, density,
and aerodynamic diameter of the powders were adequate to
allow their deposition in the deep lung. In addition, these
formulations disperse easier than other dense particles
allowing for efficient delivery of large quantities of powder
from any inhaler device. These dry powder formulations were
administered to guinea pigs by the pulmonary route and the
extent of the immune response generated in the systemic
circulation and in the lungs was evaluated. Where humoral
immunity is thought to be important in preventing disease,
the most frequently measured parameter associated with
vaccine performance is the antigen-specific IgG serum anti-
bodies present. In addition to measuring the serum IgG, the
antigen-specific IgA antibodies, an indicator of mucosal
immunity, were measured in the bronchio-alveolar lavage
fluid of the lung in the present studies.
Various animal models (e.g., primate, tree shrew, wood-
chuck, squirrel, and several avian species) have been used to
study the pathogenesis of hepatitis B; most of these animals
are not easily available or are difficult to handle in captivity
(27). The hepatitis B transgenic mouse model has been
extensively used in the study of viral hepatitis B (27), but
mouse strains have demonstrated intra-species variations to
vaccine and adjuvants (28). The guinea pig, on the other
hand, has been used in previous hepatitis B vaccine studies to
investigate the antibody response to novel vaccines (29–32).
These studies describe guinea pigs as highly sensitive to
HBsAg and that they produce a significant antibody response
to both novel and the standard human hepatitis B vaccine.
Furthermore, it is suggested that the guinea pig is a good
model for predicting human responses to candidate hepatitis
B vaccines.
The current vaccines against hepatitis B consist of either
plasma-derived HBV S protein or recombinant HBsAg, both
given a minimum of three times with the alum adjuvant; two
doses given 1 month apart and a third dose given 6 months
after the second dose. Increasing the interval between the
first and second dose of the vaccine has an insignificant effect
on the final antibody titer. Longer intervals between the last
two doses in humans result in higher final antibody levels
(33). This pattern was also observed in our study after
administering the formulations by the pulmonary route, as
well as by the intramuscular route. The antibody titers
appeared to increase significantly after the third boost in all
the immunized groups irrespective of the route of admin-
istration; the spacing between the last two boost was 75 days
compared to 30 days between the prime, first, and the second
boost. In addition, after the third and final boost, the antibody
response observed in most of the immunized animals was not
only more rapid but also reached higher and more persistent
serum levels (Fig. 2).
Since a dry powder vaccine against hepatitis B has never
been examined in an animal model, the initial study design
considered having one prime and three booster doses.
However, Fig. 2a demonstrates that one prime and two
booster doses are sufficient to provide as well as maintain
high IgG titers (>10 mIU/ml) in the systemic circulation for
60 days after the second booster (prior to the last immuniza-
tion). A long-term study is required to examine the effect of
number of doses on sustaining the antibody levels above
10 mIU/ml.
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According to Fig. 2a, groups administered with dry
powder vaccines by the pulmonary route required more time
to induce IgG titers similar to AlumAg after the first
immunization. However, the IgG titers raised by the dry
powder vaccines at the first blood sampling point should be
sufficient to provide protection (titers >10 mIU/ml). Besides,
based on the IgA titer values at week24 (Fig. 3b) for the dry
powder vaccines compared to the control AlumAg/IM, we
can infer that the former may have had a higher IgA titer in
the lungs at early time points; this may be critical for hepatitis
B infections entering through the mucosal route. However,
future studies needs to be performed to establish the IgA
response in the lungs at various time points after administer-
ing each immunization dose.
Incorporation of L-leucine in the aerosol formulation
prior to spray drying affects the surface properties of PLGA/
PEG particles leading to improvement in powder flowability
and aerosolization properties (34,35). This would in turn
increase the respirable fraction of the total dose. Surface
antigen encapsulated in nanoparticles and spray dried with
leucine were sticky and exhibited strong inter-particulate
cohesion leading to poor flow properties. These formulations
administered as dry powder to the lungs elicited a smaller
IgG immune response compared to those immunized by the
IM route, at all sampling time points; spray-dried nano-
particles containing antigen delivered by the IM route may
rapidly release antigen. When administered as aggregated dry
powders, the antigen may be deposited in the upper airways
leading to mucociliary clearance.
The significantly higher IgG response elicited by the
AlumAg group could not be matched by other formulations
irrespective of administering them by the IM or pulmonary
route primarily due to the presence of alum; it was shown that
when HBsAg was administered with alum to mice, it
increased the anti-HBs titers nearly sevenfold compared to
administering antigen without alum (36). Free and nano-
particle encapsulated rHBsAg spray dried with leucine
(AgNFSD) elicited an IgG immune response in the systemic
circulation which was slightly smaller than AgNASD when
administered by the pulmonary route (Figs. 3a and 4). The
antibody response observed in the former group may be
explained by the action of the free rHBsAg present in the dry
powder formulation rather than the antigen being present
inside the nanoparticles.
Persistence of antibodies against rHBsAg is dependent
upon the peak antibody response after the full vaccination
course (37). There is a rapid decline in protective antibody in
the first 12 months in humans after the last dose and a more
gradual decline over time. In 30-60% of adult vaccinees, the
levels decline to less than 10 mIU/ml by 10 years after
vaccination (38).
Individual serum samples from each group were ana-
lyzed to determine the level of seroprotection conferred to
single animals and to ascertain the variability in response to
dry powder administration to the lungs. This study demon-
strated that vaccination by the pulmonary route in guinea pigs
generated an IgG antibody response to values much higher
than 10 mIU/ml after the primary course of vaccination. This
response is considered to be protective in nature.
Unlike serum IgG titers, IgA antibodies generated in the
lungs were higher for guinea pigs receiving the novel dry
powder formulations by the pulmonary route compared to
those subjected to IM delivery (Fig. 3b). AgNFSD adminis-
tered guinea pigs yielded a significantly higher IgA response
than the AlumAg group, establishing the fact that alum
containing vaccines are poor generators of mucosal immune
response (39). Indeed, guinea pigs receiving alumAg by the
IM route, which elicited a high systemic IgG response, had
low IgA titers in the BAL fluid in the lungs at week24 after
first immunization. Thus, the administration of parenteral
vaccines containing alum has the propensity to elicit high IgG
titers in the serum but may not be sufficient to evoke an IgA
mucosal response in the lungs which is desirable to prevent
dissemination of disease. We did not examine the IgG titers in
the BAL fluid though they are elicited significantly in
response to infection or vaccination. The IgG in BAL fluid
approximates the serum value, with the majority of it coming
from transudation from the plasma compartment.
Therefore, the lungs may prove a promising alternative
route for administration of novel hepatitis B vaccines. The
requirement for adjuvancy, whether by incorporation of a
known adjuvant or through reformulation and dosing consid-
erations, was indicated by the absence of significant IgG titers
in the serum of guinea pigs immunized by the pulmonary
route with the dry powder formulations in the absence,
compared to that in the presence of adjuvant. Interestingly,
IgA titers in the lungs were higher when these powder
formulations were administered by the pulmonary route
compared to hepatitis B surface antigen administered by the
IM route along with alum. Currently, alum is the only
approved adjuvant for human vaccines including multiple
HBsAg vaccine though it is yet to be approved for use in the
lungs. Protective efficacy studies could not be performed in
guinea pigs due to the species specificity of HBV.
The mechanism by which sufficient serum antibody titers
are developed after delivering antigens to the lungs is not
clearly understood, but may be due to the presence of antigen
presenting cells and the proximity to the mediastinal lymph
nodes. However, other factors may be involved. Undoubt-
edly, further studies are required to explore the mechanisms
involved.
Hepatitis B vaccine aerosols delivered to the lungs show
promise for future use in humans. However, there are a few
limitations with the delivery of vaccines to the lungs. High
variability in the delivered dose was observed for dry powder
formulations administered by the pulmonary route in our
study; this was evident by the high standard error observed in
groups receiving this treatment. The lungs as an organ may
also be more sensitive to foreign antigens which may lead to
more adverse reactions.
CONCLUSION
The present studies demonstrate that pulmonary immu-
nization with dry powder formulations of hepatitis B antigen
is possible. An immune response, as measured in terms of
IgG levels, in the systemic circulation equivalent to that
elicited following parenteral administration was demonstra-
ted. In addition, a significant response, in terms of local IgA
levels, was achieved in the lungs, following aerosol admin-
istration. It may be concluded that the lungs would be a
suitable route of administration that offer not only clinical
336 Muttil et al.
advantages but also the pharmaceutical advantages of
absence of needles and cold chain for delivery globally.
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